Hansoh Pharma's Olatorepatide Demonstrates Superior Gastrointestinal Safety and Efficacy in Phase III Obesity Trial

On March 7, 2026, Hansoh Pharma (03692.HK) announced its first weight-loss drug – a dual agonist of glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor (GIPR).Olepeptide (HS-20094), conducted among overweight or obese adult subjects in ChinaThe First Phase III Clinical Trial Achieves Primary Endpoint.

This randomized, double-blind, placebo-controlled study, conducted across 33 clinical centers in China with a total of 604 adult subjects enrolled, showed:At 48 weeks of treatment, the average weight reduction from baseline in the Olerpitol group was up to 19.3%, with the proportion of participants achieving a weight reduction of ≥5% reaching up to 97.2%.

More notably, the study also demonstrated excellent gastrointestinal tolerance performance——The incidence of nausea is less than 10% on average, and the incidence of vomiting is less than 5% on average.

If the first half of the weight-loss track was about single-target drugs reshaping the efficacy paradigm, thenThe second half has already begun, centered on "multi-target synergy" and "compliance optimization."Against this backdrop, Hansoh Pharma is leveraging the significant differentiated advantages of Olebropin to secure a key position in the global race for GLP-1R/GIPR dual-target therapies.

Olepeptide submitted an impressive "report card".

On the one hand, the average weight loss of existing GLP-1 drugs ranges from 5% to 21%, with observation periods mostly lasting 60 or 72 weeks. As for Olebogepatide,A weight loss of 19.3% was achieved after just 48 weeks of treatment.And the research showsThe continuous decline in body weight indicates that the drug is expected to achieve more significant weight loss effects under long-term use.

On the other hand, in terms of response rate, a research report by Maike Securities shows that the response rate for liraglutide achieving weight loss of ≥5% is 63.2%.SemaglutideIncreased to 86.4%, tirzepatide further rose to 91%, while the proportion of subjects achieving ≥5% weight loss with oliceridineUp to 97.2%.

From this perspective, Oleb peptideExpected to rank among the "first tier" of global weight-loss drugs.The principal investigator of the study, Professor Linnong Ji, Director of the Endocrinology Department at Peking University People's Hospital, commented that Olerp肽 has demonstrated weight loss efficacy comparable to other weight loss drugs targeting the same site.

The excellent report card is inseparable from the dual-target mechanism advantage of Oley Peptide.

The Evolution of Global Weight-Loss Drug Development: A Clear Path of Mechanism Iteration

From the initialLiraglutide, to semaglutide, and now to tirzepatide and other GLP-1R/GIPR dual-target agonists, the weight loss efficacy shows a gradient increasing trend. According to the review, after adjustment in phase III clinical placebo, the weight loss of liraglutide is 5.40%, and semaglutide reaches 12.50%,And tirzepatide further increased to 20.10%.

Fang Hongjuan, Director of the Endocrinology Department at Aviation General Hospital, once explained that compared with single-target drugs, GLP-1R/GIPR drugs not only suppress appetite, delay gastric emptying, and enhance satiety through the central nervous system, but also directly act on white adipose tissue to improve energy metabolism. "Theoretically, dual-target drugs have better weight loss effects."It can achieve a '1+1>2' effect in controlling blood sugar and managing weight."

In addition to efficacy, the commercial potential of dual-target agonists has been fully validated——In 2025, Eli Lilly's tirzepatide reached the top of the global "blockbuster drug" throne with $36.5 billion in sales.

Moreover, the entire track is still accelerating advancement. According to VCBeat's NextPharma^®Database, Amgen,Merck & Co.Such multinational pharmaceutical giants,And in China, Biotechs represented by Hansoh Pharma are advancing similar pipelines, with GLP-1R/GIPR drugs poised for an NDA boom.

If efficacy is the "entry ticket" for weight-loss drugs, then gastrointestinal tolerability is the "watershed" that determines their market success.

Gastrointestinal adverse events (nausea, vomiting, diarrhea) are common side effects of GLP-1 class drugs and an important factor leading to discontinuation. According to reports, there are no shortage of users sharing their "painful experiences" on social platforms.

Professor Juan Liu, Deputy Chief of the Endocrinology Department at the First Affiliated Hospital of Sun Yat-sen University, once pointed out that this is a relatively common adverse reaction to the use of GLP-1 receptor agonists.Patients with a history of gastric diseases, especially those with gastrointestinal motility disorders, may experience more pronounced reactions.

Gastrointestinal tolerance has always been a core obstacle in improving patient treatment compliance.

Olepeptide, on the other hand, has demonstrated clear differentiation advantages in this aspect:The incidence of nausea is less than 10% on average, and the incidence of vomiting is less than 5% on average., gastrointestinal safety was good. Hansoh Pharma emphasized that, compared with the published Phase III trial data of GLP-1 related dual agonist drugs, the incidence of gastrointestinal adverse events and the discontinuation rate of treatment for Olepeptide were lower.

According to the research report by VCBeat:

Studies have pointed out that GLP-1/GIP dual-target agonists can not only exert synergistic effects but also reduce side effects such as nausea and vomiting, which is precisely confirmed by Olepreotide.

Professor Ji Linong frankly stated that the gastrointestinal tolerability characteristics of Olebrop肽 are more conducive to improving the acceptability and compliance of the treatment.This is where Olepeptide differentiates itself from similar drugs.

In addition, olepeg may also help expand the applicable population, making it more attractive to mildly obese/overweight individuals who fear side effects; and enhance clinical confidence by providing doctors with a more "controllable" treatment option.

More noteworthy is that,International Recognition from Top Pharmaceutical Companies Further Validates the Differentiated Value of Oleprobate——In June 2025, Hansoh Pharma signed an exclusive licensing agreement with Regeneron, granting it global rights to develop, manufacture, and commercialize Olepletide, with a total transaction value potentially exceeding $2 billion. Hansoh Pharma may receive double-digit sales royalties in the future.

The remarkable performance of Olepeptide marks that Hansoh Pharma's layout in the weight-loss metabolism field has begun to pay off. Meanwhile, this 30-year-old innovative pharmaceutical company is still...Build a diversified weight loss pipeline matrix,Rather than a single breakthrough.

Hansoh Pharma, founded in 1995, is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases. In the first half of 2025, Hansoh Pharma's total revenue reached 7.434 billion yuan, of which the sales revenue of innovative drugs and collaborative products amounted to 6.145 billion yuan, accounting for 82.7% of the total revenue.

In the field of weight loss and metabolism, Hansoh Pharma has formed a clear step matrix - including injectable GLP-1R/GIPR dual-target agonists represented by Oleblobotide.There is also an oral small molecule GLP-1 receptor agonist HS-10535, achieving a multi-mechanism product combination of injection + oral administration.

Current oral weight-loss drugs are becoming a new market hotspot.

In January 2026, Novo Nordisk's GLP-1 class oral weight-loss drugWegovyListed in the U.S., UBS expects that in the first quarter, the drugPrescription volume can reach 400,000, significantly exceeding market expectations.

Some experts pointed out that oral weight-loss drugs are not merely a substitute for injectable products,The target population can also be expanded to include those with mild obesity, overweight individuals, and those with preventive needs. The market positioning will shift from the original obesity treatment to a broader weight management market.

Goldman Sachs predicts that the global weight loss drug market size is expected to exceed 100 billion US dollars by 2030. By 2030 and 2035, oral weight loss drugs will respectivelyAccounting for 24% and 32% of the weight-loss drug market.

Hansoh Pharma has also gained recognition from international giants in this field.

In December 2024, Hansoh Pharma signed a global exclusive licensing agreement with Merck for HS-10535. Hansoh Pharma received an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments, as well as royalties based on product sales.

What is also worth noting is that, relying on strong clinical transformation capabilities,Hansoh Pharma Plans to Submit New Drug Application for Olebogepin Injection for Long-Term Weight Management in China Soon

Moreover, Hansoh Pharma has already commercialized seven innovative drugs in China, establishing a mature commercial network. It has accumulated extensive experience in channel access, academic promotion, and market coverage, laying a solid foundation for the future rapid scaling-up of Oleprobio.

In summary, after the pioneering products validated the efficacy potential of dual-target therapies, the industry competition focus began to gradually shift towards optimizing long-term treatment experience and adherence.

The potential balance demonstrated by Olepeptide in terms of efficacy depth and tolerability reflects a new phase in the development of weight-loss drugs by innovative Chinese pharmaceutical companies——No longer停留在仅仅靶点层面的跟随，而是通过解决临床实际痛点，探索更具差异化价值的产品路径。

As the future listing application progresses and the global collaboration with Regeneron continues to deepen,Olepeptide is expected to become one of the important representatives of China's weight loss innovative drugs on the international stage.